An observational study in Psoriasis, sponsored by Royal United Hospitals Bath NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Royal United Hospitals Bath NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 157 studies in Psoriasis with a site in United Kingdom — 9 open to participants now, 16 under way, 9 of them phase 3. Psoriasis · United Kingdom.
Among the 157 studies in Psoriasis with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 21 observational ones that give a count, is one of 5 that started in 2025, is one of 21 observational ones, reaches primary completion later than 6 of the 15 other live ones, and was the 153rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →9 of the 157 studies in Psoriasis with a site in United Kingdom are open now. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United Kingdom, United States, Canada and 10 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United Kingdom, United States, Argentina and 22 more countries
Ages 40+
LEO Pharma · Sites in United Kingdom, United States, Canada and 2 more countries
Ages 18+
Royal Free Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
University of Oxford · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
157 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 29 · Phase 3 67 · Phase 4 13
First in 2001; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 366 is above the median of 199 across 407 observational studies indexed under Psoriasis.
Median enrollment 250 across the 135 interventional studies, 412 across the 21 observational. Of the 137 that completed or were terminated, 77 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
143 of 157 have an industry lead sponsor. The 10 most frequent:
Royal United Hospitals Bath NHS Foundation Trust is the lead sponsor of 19 studies on the registry; 7 are open to participants now.
Royal United Hospitals Bath NHS Foundation Trust has 2 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
3 of the studies in Psoriasis with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07846813University of EdinburghEvidencing Vibroacoustic Sensing for Inflammatory Skin Disease Monitoring | 2026-12-31 |
| NCT07417995Royal United Hospitals Bath NHS Foundation TrustA Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis | 2027-06 |
| NCT07013201LEO PharmaA 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis | 2027-06-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 157 studies in Psoriasis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Psoriasis is a common skin condition that leads to patches of scaled skin which can be inflamed, sore and itchy. It can affect any area of skin on the body, as well as nails, and can be widespread and severe. Over the past 20 years, many new treatments have been developed and approved for severe psoriasis. Most of these newer treatments are given by injection and, as a group, are known as biologics. Many people respond well to biologics and have a meaningful improvement in their condition. There is a smaller proportion of people who do not respond well, or develop side effects, and so must switch drugs to try and improve their condition. In some cases, people need multiple lines of biologic treatment. Currently very little is understood about how well people respond when they are treated with three or more biologics in a row, as very few trials have been done in these cases.
This study aims to use data from people who have already been treated with biologics by their Dermatology teams in the NHS and use the information obtained during their normal clinic appointments to investigate this question. The investigators will assess how well people respond to each line of biologic drug (1st to 10th). They will look at whether people respond as well or less well over time, the more biologics they have. People can be included in the research if they are 18 or over and have been treated with a biologic for psoriasis in participating hospitals in the NHS in England. In this study the investigators are assessing data from events that have previously happened, and so no extra visits are required
STEPS is a retrospective observational cohort study, which will evaluate previously obtained data that had been collected in the process of routine Dermatology appointments. NHS Dermatology centres from around the United Kingdom will be recruited as sites and will submit data on patients with psoriasis treated with biologic drugs (1st to 10th line), from looking through their previous medical notes. All data submitted will be anonymous, as no identifying information will be included in the submissions. An online survey will be developed on the online platform RedCAP to collect and store the data.
Each participant will have information submitted including demographic information like age and sex, as well as information about their psoriasis and treatments. The psoriasis scores (Psoriasis Area and Severity Index and Dermatology Life Quality Index) at baseline of each line of drug, and then at the 3 and 6 month follow up appointments for each line of drug, will be submitted. These measures will be used to determine if there was an improvement in psoriasis with each line of drug, if so what level of improvement, and to compare the response in the different lines of biologic. The hypothesis is that the response at 3 months to each line of biologic does not reduce with increasing lines of biologic after the 2nd line.
As all the information to be submitted has been previously obtained in routine clinics, no additional visits or changes to any medication or monitoring will be required for any participants.
The sample size calculation suggested that a minimum of 610 treatment courses (lines of biologic treatment) are needed to undertake a meaningful analysis, which equates to data on 366 patients. To account for missing data, which is inevitable with observational data, the aim is to recruit 7-8 sites, who will each submit data on 50 patients. The investigators aim for data submission to be completed within 6 months of the start of the study, and that analysis will take a further 6 months.
Participants taken from population who have been treated with biologics and targeted synthetic treatments in Dermatology departments at participating NHS sites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants previously treated with 2 lines of biologic or targeted synthetic treatment for psoriasis.
Participants previously treated with 3 or more lines of biologic or targeted synthetic treatment for psoriasis.
PASI75
75% improvement in Psoriasis Area and Severity Index (PASI)
Time frame: 12-16 weeks and 6 months
PASI90
90% improvement in PASI score
Time frame: 12-16 weeks and 6 months
PASI100
100% improvement to PASI score
Time frame: 12-16 weeks and 6 months
PASI<2
Achievement of a PASI score \<2
Time frame: 12-16 weeks and 6 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — IPD (fully anonymised) would be shared upon reasonable request from other researchers.
Started Oct 2025 (actual). Primary completion is estimated for Aug 2026, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal United Hospitals Bath NHS Foundation Trust